-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 22, 2021, Bayer announced that the European Commission had approved the marketing authorization for Verquvo™ (2.
Verizilq is a soluble guanylate cyclase stimulant for the treatment of adult patients with symptomatic chronic heart failure (after a decrease in ejection fraction, a recent decompensation event requiring intravenous therapy has stabilized)
The lead investigator of the Phase III VICTORIA clinical trial, Charité Professor of Internal Medicine and Cardiology, Dr.
Velixiqua has been approved by the U.